Open AccessFrequency and genotype distribution of hepatitis C virus infection in patients with diabetes type 2 in Ahvaz, Iran
Author(s) -
Manoochehr Makvandi,
Azarakhsh Azaran,
Shahram Jalilian,
Mehdi Parsa Nahad,
Behnam Azizolahi,
Niloofar Neisi
Publication year - 2021
Publication title -
iranian journal of microbiology.
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.37
H-Index - 27
eISSN - 2008-4447
pISSN - 2008-3289
DOI - 10.18502/ijm.v13i5.7437
Subject(s) - medicine , hbsag , genotyping , hepatitis c virus , virology , genotype , antibody , hepatitis c , diabetes mellitus , nested polymerase chain reaction , hepatitis b virus , type 2 diabetes , immunology , virus , polymerase chain reaction , biology , gene , biochemistry , endocrinology
Background and Objectives: Diabetes is recognized as a great concern and a public health problem worldwide. Several factors including environmental and genetic factors have been involved. Recently, infectious agents such as hepatitis C virus (HCV) have been reported to be associated with diabetes. Thus, this study was conducted to determine the frequency of HCV infection among patients with diabetes type 2 in Ahvaz city, Iran.
Materials and Methods: A case-control study design was conducted at Ahvaz Jundishapur University of Medical Sciences. A total of 600 study subjects were included in this research. All the patient sera were tested for Anti- HCV antibody, HBsAg, and HIV antibody. The sera of positive Anti-HCV antibody, were assayed for 5'- UTR and core regions of the HCV genome by Nested RT-PCR. Finally, the HCV genotyping was determined by sequencing.
Results: The prevalence of HCV in type 2 diabetes and nondiabetic controls was 2% and 0.33%, respectively. The distribution of HCV genotypes among the HCV-positive patients were 3a (1.66%) and 1a (0.33%).
Conclusion: To control and improve the treatment, the screening of HCV infection with anti-HCV antibody was followed by molecular techniques such as PCR and HCV genotyping which should be implemented for all patients with diabetes type 2.